Optomed - Health technology company

Stocks
5879

I was discussing the Lumo Aeye FDA process with Grok. Mr. Grok stated that approval could be obtained in Q4 2026 or Q1 2027.

What are your thoughts on Grok’s report?

““““““““““

Yes, I fully understand your point – and the answer is partly yes, partly no. In a 510(k) process like Optomed’s (such as for Lumo + AEYE Health DR-AI), a new large prospective clinical trial (pivotal trial) is not usually required. Often, a bridging study or real-world data from the old Aurora + new Lumo images is sufficient. Therefore, a large registered trial may not be necessary at all.

  1. Large clinical trial (pivotal / Phase III type) → when will it appear on ClinicalTrials.gov?

  • If the study meets FDAAA 801 criteria (“applicable clinical trial”):

    • Intervention (not just observation)

    • Phase 2 or later

    • Concerns a serious condition (such as diabetic retinopathy)

    • For FDA regulation
      → Registration is mandatory before the first patient is enrolled.
      It will appear on ClinicalTrials.gov as soon as the sponsor (Optomed/AEYE) submits the information – usually weeks to months before initiation. Results must also be reported later.

  • Historical example: Aurora + AEYE’s original approval was based on two large prospective Phase III trials → one of them (NCT04612868) is registered.

In the Lumo Aeye case, there is currently no entry on ClinicalTrials.gov (nor in recent searches for 2026). This suggests that the process does not require a new large registered trial.

  1. Smaller study (bridging, validation, real-world data) → will it necessarily appear on ClinicalTrials.gov?
    Not necessarily at all.

  • Most 510(k) updates (new camera + existing AI) use:

    • Retrospective data (old images)

    • Real-world evidence (images from already sold Lumo cameras)

    • A small internal validation study

  • These are not “applicable clinical trials,” so registration is not mandatory.

  • Many AI manufacturers (EyeArt, IDx-DR, etc.) have obtained 510(k) updates this way without a new public trial.

  • The “large amount of image data” mentioned in Optomed’s Q4/2025 interview refers precisely to this: data is collected from the field (already sold Lumo cameras) without a separate registered study.

Optomed’s directed share issue (“the issue”) in December 2025
Yes, Optomed raised approximately 6 million euros through a directed share issue on December 10, 2025 (1.76 million new shares at €3.40).
The company officially stated that the funds would be used for:

  • strengthening the balance sheet

  • product development

  • commercialization of AI solutions

  • implementation of the growth strategy.

    optomed.com

This covers both the Lumo Aeye process and potential Lumo + Toku CLAiR studies (cardiac risk assessment from retinal images, “Lumo Clair” is exactly this combination, partnership from 2024).

Are they intentionally delaying registration and disclosure?
Yes, this is entirely possible and a common practice (and it is not illegal). The reasons you mentioned are real:

  • Customer cannibalization: If customers know that Lumo Aeye is coming soon, they may wait for it instead of Aurora (Lumo is lighter and more versatile).

  • Keeping competitors in the dark: AEYE Health, Aireen, Toku, etc., want to keep technical advances secret for as long as possible.

  • As a public company, Optomed cannot conceal material information, but “we are collecting image data for AI approval” is not always material information that needs to be disclosed to the stock exchange immediately.

Summary of timeline (estimate based on April 2026 situation):

  • If it’s a real-world/bridging model → approval could come in Q4/2026 or Q1/2027 without any entry appearing on ClinicalTrials.gov.

  • If the company decides to conduct a small prospective validation study → it may not be registered.

  • A large trial → would become visible as soon as enrollment begins (but it does not appear to be underway).

““““““““““

6 Likes